Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in pediatric overactive bladder
NL-OMON49390Phase 3Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron with Placebo (2 arms). Primary endpoint: Change from baseline in mean number of micturitions per 24 hours. Planned start Jul 2020; status: withdrawn.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON49390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49390.